SCHEMBL24155504

SCHEMBL24155504

Nc1cc(-c2cnc(Oc3cccc(F)c3)nc2)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
HTT P42858 1/20 0.43
EGFR P00533 2/20 0.41
BTK Q06187 2/20 0.41
ALOX5AP P20292 2/20 0.40
FEN1 P39748 2/20 0.40
MAP4K4 O95819 1/20 0.40
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GRM5 P41594 1/20 0.39
ACACB O00763 1/20 0.38
USP2 O75604 1/20 0.38
S1PR1 P21453 1/20 0.37
ROCK1 Q13464 2/20 0.36
CYP3A4 P08684 1/20 0.36
PRKACA P17612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24155829 0.89 DYRK1A (0.45) DYRK1AKMT2AMEN1EGFRBTK
SCHEMBL24156294 0.86 DYRK1A (0.49) DYRK1AKMT2AMEN1HTTALOX5AP
SCHEMBL24155609 0.85 MEN1 (0.54) DYRK1AKMT2AMEN1HTTALOX5AP
SCHEMBL24156295 0.84 EGFR (0.44) DYRK1AKMT2AMEN1HTTEGFR
SCHEMBL24156287 0.84 NOS3 (0.48) DYRK1AKMT2AMEN1HTTEGFR
SCHEMBL24156289 0.83 KMT2A (0.48) KMT2AMEN1HTTEGFRBTK
SCHEMBL13635718 0.81 NOS3 (0.50) KMT2AMEN1ALOX5APFEN1MAP4K4
SCHEMBL30483681 0.81 MAP4K4 (0.46) KMT2AMEN1HTTEGFRBTK
SCHEMBL22534733 0.81 MAP4K4 (0.46) KMT2AMEN1HTTEGFRBTK
SCHEMBL24156293 0.80 KMT2A (0.45) KMT2AMEN1HTTEGFRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B DYRK1A 3828/4885KMT2A 279/4885MEN1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.